BLFS
BioLife Solutions, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+54/100
Last price
38.61
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
38.61
Day high
38.83
Day low
36.96
Volume
0
Market cap
$1.89B
P/E (TTM)
39.00
52W range
17.86 – 39.76
Trailing performance
Returnvs SPY
1W
-1.56%
-3.5%
1M
+9.53%
+8.4%
3M
+42.00%
+37.5%
6M
+101.83%
+83.6%
YTD
+59.68%
+45.4%
1Y
+45.20%
+28.8%
3Y
+179.58%
+97.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BLFS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.27M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Mar 23, 26 | FOSTER KAREN A Officer |
SELL | 2.58K | $49.40K | Direct |
| Mar 9, 26 | FOSTER KAREN A Chief Operating Officer |
SELL | 97.42K | $1.96M | Direct |
| Mar 3, 26 | FOSTER KAREN A Officer |
SELL | 418 | $8.67K | Direct |
| Mar 3, 26 | AEBERSOLD SARAH Officer |
SELL | 219 | $4.54K | Direct |
| Mar 3, 26 | MATHEW ABY J Officer |
SELL | 529 | $10.97K | Direct |
| Mar 3, 26 | WICHTERMAN TROY Chief Financial Officer |
SELL | 588 | $12.20K | Direct |
| Mar 3, 26 | WERNER SEAN Chief Technology Officer |
SELL | 111 | $2.30K | Direct |
| Mar 3, 26 | BERARD TODD C.J. Officer |
SELL | 353 | $7.32K | Direct |
| Feb 24, 26 | FOSTER KAREN A Chief Operating Officer |
STOCK | 32.11K | $0 | Direct |
| Feb 24, 26 | COSTE CATHERINE Director |
STOCK | 8.17K | $0 | Direct |
| Feb 24, 26 | AEBERSOLD SARAH Officer |
STOCK | 23.55K | $0 | Direct |
| Feb 24, 26 | DUROSS AMY Director |
STOCK | 8.17K | $0 | Direct |
| Feb 24, 26 | GOSWAMI JOYDEEP Director |
STOCK | 8.17K | $0 | Direct |
| Feb 24, 26 | MATHEW ABY J Officer |
STOCK | 59.70K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AEBERSOLD SARAH |
Officer | 93.36K | Sale |
BERARD TODD C.J. |
Officer | 165.94K | Sale |
CASDIN PARTNERS MASTER FUND, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
DE GREEF RODERICK |
Chief Executive Officer | 744.85K | Stock Award(Grant) |
ELLINGSON RACHEL H. |
Director | 57.99K | Stock Award(Grant) |
FOSTER KAREN A |
Officer | 108.76K | Sale |
GOSWAMI JOYDEEP |
Director | 53.16K | Stock Award(Grant) |
MATHEW ABY J |
Officer | 392.94K | Sale |
WERNER SEAN |
Chief Technology Officer | 49.93K | Sale |
WICHTERMAN TROY |
Chief Financial Officer | 220.65K | Sale |
Fundamentals
Market cap$1.89B
Enterprise value$1.82B
Revenue (TTM)$106.69M
Gross profit$67.87M
EBITDA$6.90M
Net income$49.21M
EPS (TTM)$0.99
Free cash flow$4.66M
Total cash$82.42M
Total debt$15.74M
Book value / share$8.59
Shares outstanding48.92M
Float40.12M
Short % of float10.82%
Dividend yield0.00%
Beta (5Y)1.82
Valuation & profitability ratios
Trailing P/E39.00
Forward P/E117.00
PEG ratio15.09
Price / sales—
Price / book4.49
EV / revenue17.07
EV / EBITDA264.00
Gross margin63.61%
Operating margin5.96%
Profit margin54.35%
Return on equity12.83%
Return on assets0.26%
Debt / equity3.75
Current ratio9.69
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $96.21M | $74.65M | $68.02M | $76.24M | +28.9% |
| Operating revenue | $96.21M | $74.65M | $68.02M | $76.24M | +28.9% |
| Cost of revenue | $34.10M | $24.55M | $26.70M | $29.33M | +38.9% |
| Gross profit | $62.12M | $50.10M | $41.32M | $46.91M | +24.0% |
| Research & development | $23.09M | $4.75M | $5.51M | $8.67M | +385.9% |
| Selling, general & admin | $55.37M | $49.56M | $54.17M | $44.93M | +11.7% |
| Total operating expense | $78.72M | $54.57M | $60.72M | $57.59M | +44.2% |
| Operating income | -$16.60M | -$4.48M | -$19.40M | -$10.68M | -270.8% |
| Net interest income | $2.71M | -$766.00K | -$1.41M | -$284.00K | +453.3% |
| Pre-tax income | -$12.08M | -$8.82M | -$12.22M | -$4.85M | -36.9% |
| Tax provision | $49.00K | -$38.00K | -$64.00K | -$5.24M | +228.9% |
| Net income | -$4.59M | -$20.18M | -$68.00M | -$139.81M | +77.2% |
| Net income to common | -$4.59M | -$20.18M | -$68.00M | -$139.81M | +77.2% |
| Basic EPS | -0.09 | -0.44 | -1.55 | -3.29 | +79.5% |
| Diluted EPS | -0.10 | -0.44 | -1.55 | -3.29 | +77.3% |
| EBIT | -$16.60M | -$4.48M | -$19.40M | -$10.68M | -270.8% |
| EBITDA | -$11.91M | $4.18M | -$7.10M | $5.79M | -384.8% |
| Basic shares | 47.75M | 46.07M | 43.72M | 42.48M | +3.7% |
| Diluted shares | 48.65M | 46.07M | 43.72M | 42.48M | +5.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $33.04M | $91.54M | $27.90M | $19.44M | — | -63.9% |
| Cash & short-term investments | $88.93M | $100.74M | $44.18M | $62.70M | — | -11.7% |
| Accounts receivable | $7.95M | $8.48M | $7.90M | $33.94M | — | -6.2% |
| Inventory | $30.16M | $29.01M | $27.16M | $34.90M | — | +3.9% |
| Total current assets | $136.56M | $148.76M | $120.60M | $138.45M | — | -8.2% |
| Property, plant & equipment | $22.18M | $16.53M | $12.57M | $39.20M | — | +34.2% |
| Goodwill & intangibles | $212.84M | $214.15M | $224.30M | $256.83M | — | -0.6% |
| Total assets | $405.88M | $399.49M | $412.71M | $450.23M | — | +1.6% |
| Total current liabilities | $22.98M | $32.73M | $42.18M | $44.58M | — | -29.8% |
| Current debt | $5.00M | $10.94M | $6.29M | $1.81M | — | -54.3% |
| Long-term debt | — | $5.00M | $17.56M | $23.79M | $6.35M | — |
| Total debt | $17.90M | $30.04M | $33.83M | $43.71M | — | -40.4% |
| Total liabilities | $34.00M | $50.58M | $75.05M | $86.04M | — | -32.8% |
| Retained earnings | -$339.70M | -$335.10M | -$314.92M | -$246.91M | — | -1.4% |
| Shareholder equity | $371.89M | $348.91M | $337.66M | $364.19M | — | +6.6% |
| Working capital | $113.58M | $116.03M | $78.43M | $93.87M | — | -2.1% |
| Net tangible assets | $159.04M | $134.76M | $113.36M | $107.36M | — | +18.0% |
| Shares issued | 48.20M | 46.91M | 45.17M | 42.83M | — | +2.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$4.59M | -$20.18M | -$68.00M | -$139.81M | +77.2% |
| Depreciation & amortisation | $4.69M | $8.66M | $12.29M | $16.47M | -45.9% |
| Stock-based compensation | $22.99M | $30.92M | $33.24M | $25.33M | -25.6% |
| Change in working capital | -$8.91M | $227.00K | $1.47M | -$14.90M | -4,024.7% |
| Operating cash flow | $20.11M | $8.43M | -$12.50M | -$8.49M | +138.6% |
| Capital expenditure | -$19.70M | -$3.53M | -$6.38M | -$10.38M | -458.5% |
| Investing cash flow | -$71.54M | $58.30M | $17.84M | -$58.12M | -222.7% |
| Financing cash flow | -$10.92M | -$6.78M | $10.59M | $16.32M | -61.0% |
| Free cash flow | $416.00K | $4.90M | -$18.88M | -$18.87M | -91.5% |
| End cash position | $33.04M | $95.39M | $35.44M | $19.47M | -65.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $28.47M | $27.50M | $18.79M | $28.07M | $23.44M | +3.5% |
| Operating revenue | $28.47M | $27.50M | $18.79M | $28.07M | $23.44M | +3.5% |
| Cost of revenue | $10.18M | $10.00M | $6.81M | $10.15M | $8.20M | +1.7% |
| Gross profit | $18.29M | $17.50M | $11.98M | $17.92M | $15.23M | +4.5% |
| Research & development | $2.96M | $2.65M | -$67.00K | $2.71M | $17.49M | +11.6% |
| Selling, general & admin | $13.48M | $14.73M | $12.54M | $14.60M | $13.81M | -8.5% |
| Total operating expense | $16.59M | $17.47M | $10.63M | $18.01M | $31.36M | -5.0% |
| Operating income | $1.70M | $27.00K | $1.35M | -$89.00K | -$16.13M | +6,181.5% |
| Net interest income | $994.00K | $1.04M | $833.00K | $508.00K | $684.00K | -4.5% |
| Pre-tax income | $2.75M | $1.25M | $3.36M | $703.00K | -$15.20M | +120.6% |
| Tax provision | -$42.35M | $62.00K | -$173.00K | $82.00K | $126.00K | -68,408.1% |
| Net income | $45.10M | $1.19M | $11.07M | $621.00K | -$15.84M | +3,703.0% |
| Net income to common | $45.10M | $1.19M | $11.07M | $621.00K | -$15.84M | +3,703.0% |
| Basic EPS | 0.92 | 0.02 | 0.23 | 0.01 | -0.33 | +4,500.0% |
| Diluted EPS | 0.91 | 0.02 | 0.22 | 0.01 | -0.33 | +4,450.0% |
| EBIT | $1.70M | $27.00K | $1.35M | -$89.00K | -$16.13M | +6,181.5% |
| EBITDA | $2.50M | $726.00K | $1.93M | $1.25M | -$14.74M | +245.0% |
| Basic shares | 48.87M | 48.46M | 48.14M | 47.93M | 47.80M | +0.8% |
| Diluted shares | 49.29M | 49.25M | 49.01M | 48.72M | 47.80M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.00M | $22.82M | $33.04M | $29.48M | $31.90M | — | +5.1% |
| Cash & short-term investments | $82.42M | $81.00M | $88.93M | $78.95M | $81.77M | — | +1.8% |
| Accounts receivable | $10.65M | $13.06M | $7.95M | $10.84M | $10.06M | — | -18.4% |
| Inventory | $35.59M | $32.83M | $30.16M | $27.82M | $27.69M | — | +8.4% |
| Total current assets | $135.20M | $133.22M | $136.56M | $126.57M | $125.43M | — | +1.5% |
| Property, plant & equipment | $23.88M | $21.62M | $22.18M | $18.73M | $17.20M | — | +10.5% |
| Goodwill & intangibles | $212.24M | $212.52M | $212.84M | $219.75M | $220.45M | — | -0.1% |
| Total assets | $447.49M | $400.91M | $405.88M | $392.08M | $387.24M | — | +11.6% |
| Total current liabilities | $13.95M | $18.25M | $22.98M | $27.15M | $28.31M | — | -23.6% |
| Current debt | — | $2.50M | $5.00M | $7.49M | $10.05M | $10.45M | — |
| Long-term debt | — | — | — | — | — | $2.50M | — |
| Total debt | $15.74M | $14.86M | $17.90M | $20.68M | $23.82M | — | +5.9% |
| Total liabilities | $27.49M | $28.68M | $34.00M | $38.34M | $40.09M | — | -4.1% |
| Retained earnings | -$293.41M | -$338.51M | -$339.70M | -$350.77M | -$351.39M | — | +13.3% |
| Shareholder equity | $420.00M | $372.23M | $371.89M | $353.74M | $347.15M | — | +12.8% |
| Working capital | $121.25M | $114.97M | $113.58M | $99.42M | $97.12M | — | +5.5% |
| Net tangible assets | $207.76M | $159.71M | $159.04M | $133.99M | $126.70M | — | +30.1% |
| Shares issued | 48.89M | 48.83M | 48.20M | 47.97M | 47.85M | — | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $45.10M | $1.19M | $11.07M | $621.00K | -$15.84M | +3,703.0% |
| Depreciation & amortisation | $809.00K | $699.00K | $586.00K | $1.33M | $1.38M | +15.7% |
| Stock-based compensation | $3.85M | $4.81M | $7.08M | $5.90M | $5.86M | -19.8% |
| Change in working capital | -$2.76M | -$6.88M | -$2.24M | -$2.99M | $85.00K | +59.9% |
| Operating cash flow | $6.35M | -$491.00K | $4.92M | $6.10M | $7.37M | +1,392.9% |
| Capital expenditure | -$1.16M | -$167.00K | -$14.48M | -$3.30M | -$1.74M | -596.4% |
| Investing cash flow | -$1.58M | -$1.83M | $1.14M | -$5.97M | -$39.53M | +13.7% |
| Financing cash flow | -$3.59M | -$7.89M | -$2.50M | -$2.56M | -$2.88M | +54.5% |
| Free cash flow | $5.18M | -$658.00K | -$9.56M | $2.80M | $5.63M | +888.0% |
| End cash position | $24.00M | $22.82M | $33.04M | $29.48M | $31.90M | +5.1% |
Options analytics
Put / call volume
0.12
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
10.00
-74.1% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+442.8%
Puts bid over calls
Call volume
17
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
10.00
2 contracts
Heaviest put OI
25.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.06 | 0.08 | +40.5% |
| Mar 2026 | 0.02 | 0.04 | +160.9% |
| Dec 2025 | 0.01 | 0.04 | +680.0% |
| Sep 2025 | 0.00 | 0.04 | +1,997.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.07 | 1 | $29.13M | +3.8% |
| Next quarter | 0.08 | 1 | $30.13M | +21.7% |
| Current year | 0.25 | 1 | $115.23M | +19.8% |
| Next year | 0.33 | 1 | $134.85M | +17.0% |
Analyst targets & ownership
Mean target$31.29
High target$33.00
Low target$31.00
Implied upside-18.97%
Analyst count7
ConsensusNONE
Strong buy / Buy0 / 1
Hold8
Sell / Strong sell0 / 0
Held by insiders2.61%
Held by institutions105.52%
Institutions holding319
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
38.33
+0.72% from price
SMA 20
37.24
+3.67% from price
SMA 50
35.87
+7.63% from price
SMA 100
31.34
+23.19% from price
SMA 200
26.69
+44.66% from price
EMA 12
37.95
+1.75% from price
EMA 26
37.11
+4.04% from price
EMA 50
35.42
+9.01% from price
RSI (14)
60.6
Neutral
MACD (12,26,9)
0.84
Hist -0.05
ATR (14)
1.05
2.73% of price
Realised vol 30D
30.1%
Annualised
Bollinger upper
40.08
20, 2σ
Bollinger lower
34.41
20, 2σ
50 / 200 cross
Golden
35.87 vs 26.69
Trend bias
Above 200
+44.66%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
30.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-37.0%
Peak to trough
Max drawdown 5Y
-84.6%
Peak to trough
ATR 14
1.05
2.73% of price
Beta (reported)
1.82
5Y monthly, from filing
Short interest
Shares short
3.88M
Prior 4.02M
Change vs prior
-3.3%
Shorts covering
% of float
10.82%
Elevated
% of shares out
7.94%
Against total outstanding
Days to cover
4.5
Liquid
Float
40.12M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 26 | Benchmark | DOWNGRADE | Buy | Hold |
| Jul 27, 26 | Stephens & Co. | DOWNGRADE | Overweight | Equal-Weight |
| Jul 23, 26 | Jefferies | DOWNGRADE | Buy | Hold |
| Jul 23, 26 | TD Cowen | DOWNGRADE | Buy | Hold |
| Jul 22, 26 | Lake Street | DOWNGRADE | Buy | Hold |
| Jul 22, 26 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Dec 29, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 24, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 8, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 13, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 6, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jan 8, 25 | Northland Capital Markets | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:14
Split dateJan 29, 2014
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-06
Proxy Statements
DEFA14A · 2026-09-30
Proxy Statements
DEFA14A · 2026-09-09
Proxy Statements
DEFM14A · 2026-09-04
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-08-03
Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
425 · 2026-07-24
Corporate Changes & Voting Matters
8-K · 2026-07-22
Headlines
Why Freshworks Stock Bumped Higher Today
Motley Fool · 7h ago
Why Are Freshworks (FRSH) Shares Soaring Today
StockStory · 8h ago
Repligen Closes BioLife Solutions Acquisition
MT Newswires · 14h ago
Repligen Completes Acquisition of BioLife Solutions
GlobeNewswire · 16h ago
Freshworks Set to Join S&P SmallCap 600
PR Newswire · 1d ago
Freshworks stock climbs on S&P SmallCap 600 inclusion
Investing.com · 1d ago
Freshworks to Join S&P SmallCap 600
MT Newswires · 1d ago
BioLife Solutions Shareholders Approve Repligen Merger Agreement
MarketBeat · 1d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.